Company: NDRA
Filing Date: 2025-10-30
Form Type: 424B5
Source: 0001213900-25-103705
Chunk: 13

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-30
Form: 424B5
Chunk 13
---
 sell the shares of our common stock to the Sales Agent as principal for its own accounts, at a price per share agreed upon at the time of sale. If we sell shares to a Sales Agent as principal, we will enter into a separate terms agreement setting forth the terms of such transaction, and we will describe the agreement in a pricing supplement. See “Plan of Distribution” on page S-21 of this prospectus supplement. |
| Use of proceeds                                   |     | We may use the net proceeds from this offering, if any, for general corporate purposes, which include, among other things, pursuit of the DAT strategy, working capital, capital expenditures, and/or investing in existing and future projects. Our management will have significant discretion and flexibility over the allocation of the net proceeds from this offering.                                                                                                                                                                                                    |
| Risk factors                                      |     | Investing in our common stock involves significant risks. See the section entitled “Risk Factors” beginning on page S-9 and the other information included or incorporated by reference in this prospectus supplement and the accompanying prospectus for a discussion of factors you should carefully consider before deciding to invest in shares of our common stock.                                                                                                                                                                                                        |
| The Nasdaq Capital Market symbol                  |     | “NDRA”                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

| (1) | The number of shares of our common stock to be outstanding after this offer is based on 1,166,441 shares 
 of common stock outstanding as of October 16, 2025 and excludes the following:                           |

| ● | 364,801 shares of common stock issuable upon the exercise of outstanding prefunded warrants issued in the Private Placement (the “Prefunded 
 Warrants”);                                                                                                                                 |

| ● | 1,669,387 shares of common stock issuable upon outstanding warrants (excluding the Prefunded Warrants); |

| ● | 1 share of common stock issuable upon the conversion of outstanding shares of Series A Convertible Preferred Stock, including shares 
 issuable in respect of accrued and unpaid dividends thereon;                                                                         |

| ● | 266 shares of common stock issuable upon the exercise of outstanding stock options issued pursuant to our 2016 Omnibus Incentive Plan 
 (the “Incentive Plan”);                                                                                                               |

| ● | 147,169 shares of common stock issuable upon the settlement of outstanding restricted stock units issued pursuant to the Incentive 
 Plan; and                                                                                                                          |

| ● | 32,336 shares of common stock reserved for future issuance under our Incentive